Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- BONE MARROW TRANSPLANTATION54(12) · pp.2051 · 2019
- 피인용
- Web of Science 5Scopus 4
- FWCI (Scopus)
- 0.17
- JCR IF
- JCR 2018 4.674
- ISSN
- 0268-3369
저자
- Lee, Yoo Jin제1저자Department of Internal Medicine, Division of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea
- Moon, Joon HoDepartment of Hematology-Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea
- Sohn, Sang KyunDepartment of Hematology-Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea
- Kim, Seok JinDepartment of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
- Jung, Sung-HoonDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea
- Lee, Je-JungDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea
- Jo, Jae-CheolDepartment of Internal Medicine, Division of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea
- 신호진Department of Internal Medicine, Division of Hematology-Oncology, School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea
- Lee, Won SikDepartment of Hematology-Oncology, Inje University Busan Paik Hospital, Busan, Republic of Korea
- Lee, Ji HyunDepartment of Internal Medicine, Dong-A Medical Center, Dong-A University College of Medicine, Busan, Republic of Korea
- Bae, Sung HwaDepartment of Hematology-Oncology, Daegu Catholic University Hospital, Catholic University of Daegu School of Medicine, Daegu, Republic of Korea
- Kim, Min KyoungDepartment of Hematology-Oncology, Yeungnam University Medical Center, Daegu, Republic of Korea
- Lee, Ho SupDepartment of Internal Medicine, Division of hematology, Kosin University College of Medicine, Kosin University Gospel Hospital, Busan, Republic of Korea
- Kim, Kihyun교신저자Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
- Min, Chang-KiDepartment of Hematology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
초록
Bortezomib/thalidomide/dexamethasone (VTD) induction therapy followed by autologous stem cell transplantation (ASCT) is one of the standard therapies for newly diagnosed multiple myeloma (NDMM). However, the appropriate depth of response to induction therapy and timing of upfront ASCT are still debated. We investigated if two additional cycles of VTD (VTD6) improved the responses and progression-free survival (PFS) compared with four cycles of VTD (VTD4). We retrospectively reviewed outcomes of 190 NDMM patients treated with at least four cycles of VTD followed by ASCT between September 2014 and August 2017 [VTD4, n = 129 (67.9%); VTD6, n = 61 (32.1%)]. The VTD6 group had a higher pre-ASCT complete response (CR) rate than the VTD4 group (31.1% versus 10.1%, P < 0.001), but, the pre- and post-ASCT >= very good partial response (VGPR), and 2-year PFS were similar. Multivariate analysis revealed age, beta(2)-microglobulin, and pre-ASCT CR as important factors for PFS. Two additional cycles of VTD prolonged PFS in patients with PR only after VTD4 [Hazard ratio (HR) = 0.29, P = 0.016] or those with Revised International Staging System stage I/II (HR = 0.36, P = 0.039). In conclusion, two additional VTD cycles may be helpful for patients with PR only after VTD4 but high risk MM needs the other treatment options.
키워드
STEM-CELL TRANSPLANTATIONTHALIDOMIDE PLUS DEXAMETHASONECOMPLETE REMISSIONINTENSIVE THERAPYBORTEZOMIBSURVIVALCRITERIAIMPACT
식별자
- Scopus EID
- 2-s2.0-85069903681
- WoS UID
- 000500920000017



로그인
연구물 목록으로